CN121511297A - 修饰噬菌体 - Google Patents
修饰噬菌体Info
- Publication number
- CN121511297A CN121511297A CN202480044785.4A CN202480044785A CN121511297A CN 121511297 A CN121511297 A CN 121511297A CN 202480044785 A CN202480044785 A CN 202480044785A CN 121511297 A CN121511297 A CN 121511297A
- Authority
- CN
- China
- Prior art keywords
- bacteriophage
- genome
- phage
- nucleic acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023-116013 | 2023-07-14 | ||
| JP2023116013 | 2023-07-14 | ||
| PCT/JP2024/025265 WO2025018295A1 (ja) | 2023-07-14 | 2024-07-12 | 改変バクテリオファージ |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN121511297A true CN121511297A (zh) | 2026-02-10 |
Family
ID=94282182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202480044785.4A Pending CN121511297A (zh) | 2023-07-14 | 2024-07-12 | 修饰噬菌体 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4745231A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2025018295A1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN121511297A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202517778A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2025018295A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN122060690A (zh) * | 2026-04-01 | 2026-05-19 | 深圳市百泽诺科生物技术有限公司 | 一种分枝杆菌噬菌体及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3358015A1 (en) * | 2017-02-03 | 2018-08-08 | Eligo Bioscience | Optimized vector for delivery in microbial populations |
| US11066691B1 (en) * | 2018-09-14 | 2021-07-20 | National Technology & Engineering Solutions Of Sandia, Llc | Therapeutic phages and methods thereof |
| CN114981408A (zh) * | 2019-11-06 | 2022-08-30 | 洛可斯生物科学公司 | Crispr cas系统和溶原性模块 |
| WO2021092362A1 (en) | 2019-11-07 | 2021-05-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of specific phages for the treatment of nontuberculous mycobacteria (ntm) infections |
| JP2023116013A (ja) | 2022-02-09 | 2023-08-22 | セイコーエプソン株式会社 | 測色装置 |
| EP4516898A4 (en) * | 2022-04-28 | 2026-05-06 | Arrowsmith Inc | BACTERIOPHAGE |
-
2024
- 2024-07-12 EP EP24843086.0A patent/EP4745231A1/en active Pending
- 2024-07-12 TW TW113126207A patent/TW202517778A/zh unknown
- 2024-07-12 CN CN202480044785.4A patent/CN121511297A/zh active Pending
- 2024-07-12 WO PCT/JP2024/025265 patent/WO2025018295A1/ja not_active Ceased
- 2024-07-12 JP JP2025534031A patent/JPWO2025018295A1/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN122060690A (zh) * | 2026-04-01 | 2026-05-19 | 深圳市百泽诺科生物技术有限公司 | 一种分枝杆菌噬菌体及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2025018295A1 (cg-RX-API-DMAC7.html) | 2025-01-23 |
| WO2025018295A1 (ja) | 2025-01-23 |
| EP4745231A1 (en) | 2026-05-20 |
| TW202517778A (zh) | 2025-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7163818B2 (en) | Bacteriophage having multiple host range | |
| US8535939B2 (en) | Transfection vector | |
| US6896882B2 (en) | Lysin-deficient bacteriophages having reduced immunogenicity | |
| US11590215B2 (en) | Process for the production of a DNA vaccine for cancer immunotherapy | |
| JP2011504366A5 (cg-RX-API-DMAC7.html) | ||
| EP4032526A1 (en) | Bacteriophage for modulating inflammatory bowel disease | |
| Zheng | Effects of intratumoral microbiota on tumorigenesis, anti-tumor immunity, and microbe-based cancer therapy | |
| EP4516898A1 (en) | Bacteriophage | |
| Suvorov et al. | Construction of the enterococcal strain expressing immunogenic fragment of SARS-CoV-2 virus | |
| WO2025018295A1 (ja) | 改変バクテリオファージ | |
| Adamczyk-Popławska et al. | The potential for bacteriophages and prophage elements in fighting and preventing the gonorrhea | |
| JP4495143B2 (ja) | 生物学的安全性が向上した経口ワクチン接種用凍結乾燥形態のコレラ菌弱毒化株 | |
| EP3215174B1 (en) | Monocins and methods of use | |
| AU2018217936A1 (en) | Rebooting of synthetic bacteriophage genome in L-form bacteria | |
| JP7836794B2 (ja) | 遺伝子操作された、生きている細菌及びその構築方法 | |
| CA2504331A1 (en) | Bacteriophage having modified holin and uses thereof | |
| JP2023528151A (ja) | エンテロシンおよびその使用方法 | |
| US20240254167A1 (en) | Genetically modified clostridium strains expressing recombinant antigens and uses thereof | |
| Kalarus | Deletion of prophages in Clostridioides difficile | |
| Lança | Studies on the regulation of bacteriocin loci in Streptococcus mitis | |
| Borralho | Studies on the regulation of bacterioci loci in Streptococcus mitis | |
| Hossain | Molecular Interactions between phage and the catfish pathogen Edwardsiella ictaluri and Comparative Genomics of Epidemic strains of Aeromonas hydrophila | |
| CN121950722A (zh) | 一种基于T4gp10样结构域的工程化噬菌体构建平台 | |
| Schmitz et al. | Identifying phage lytic enzymes: past, present, and future |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |